Melanocyte antigen recognized by T cells 1 (MART-1)

Melanocyte antigen recognized by T cells 1 (MART-1), also known as Melan-A or MLANA, is a type III transmembrane protein comprising 118 amino acids, with a single transmembrane domain and a molecular weight of approximately 13 kDa[2][1]. It is encoded by the MLANA gene on chromosome 9[2][6]. MART-1 is specifically expressed in melanocytes, melanoma cells, and retinal pigment epithelium, but not in most other tissues[2][1][6]. MART-1 is critical for melanosome biogenesis and pigmentation, functioning partly by stabilizing and trafficking the PMEL17/GP100 protein, which is essential for forming the internal structure of melanosomes[6][4][7]. In the immune system, fragments of MART-1 (notably the 26-35 and 27-35 peptide regions) are presented by MHC class I complexes on melanoma cells, making it a major target for cytotoxic T lymphocytes and a focus of adoptive T-cell immunotherapy and peptide vaccine strategies against melanoma[2][1]. In clinical pathology, MART-1/Melan-A expression serves as a sensitive and specific biomarker for melanocytic lineage, aiding in the diagnosis of melanoma and distinguishing it from other tumors[2]. However, its use as a therapeutic target is complicated by its presence in normal melanocytes and benign nevi, raising potential for off-target immune reactions[2]. No approved drugs directly target MART-1, but it is an important immunotherapeutic antigen in ongoing cancer vaccine and adoptive cell therapy research[2][1].

Other names

Melan-AMLANAMelanoma antigen recognized by T cells 1MART-1melanocyte antigen

Antigenic peptide presentation to CD8+ cytotoxic T lymphocytes; targeted in cancer vaccines to elicit T cell immune response against melanoma cells